- Home
- HSCS vs BRTX Comparison
HSCS vs BRTX Comparison
Compare HSCS & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSCS | BRTX |
|---|---|---|
| Founded | 2007 | 1997 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | Medical Specialities | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 6.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | HSCS | BRTX |
|---|---|---|
| Price | $1.70 | $0.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 22.5K | ★ 23.8M |
| Earning Date | 03-16-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $298.39 |
| Revenue Next Year | N/A | $64.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.63 | $0.16 |
| 52 Week High | $6.47 | $2.04 |
Technical Indicators
Market Signals| Indicator | HSCS | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.79 | 80.65 |
| Support Level | N/A | $0.20 |
| Resistance Level | $2.16 | $1.20 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 39.84 | 62.90 |
Price Performance
Historical ComparisonAbout HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.